MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio

MaxCyte, Inc. (NASDAQ:MXCT) is one of the Best 52-Week Low Penny Stocks to Buy Now. On August 4, MaxCyte, Inc. (NASDAQ:MXCT) announced signing a strategic platform license with Adicet Bio, Inc. Adicet focuses on developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.

As part of this agreement, Adicet gets non-exclusive rights to use MaxCyte, Inc.’s (NASDAQ:MXCT) Flow Electroporation technology and ExPERT platform for research, clinical, and commercial purposes. The company has developed a unique process to activate and grow specific gamma delta T cells, enabling large-scale production of off-the-shelf cell therapies ready for clinical use. The approach combines non-viral gene editing with an efficient expansion system to create powerful therapies aimed at treating various cancers and autoimmune conditions. MaxCyte, Inc.’s (NASDAQ:MXCT) ExPERT technology offers advanced electroporation tools that ensure high gene transfer efficiency, cell viability, and scalability.

MaxCyte, Inc. (NASDAQ:MXCT) develops advanced cell-engineering technologies to help biotech and pharmaceutical companies create next-generation cell therapies.

While we acknowledge the potential of MXCT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.